看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
' x' {% G# t) R$ }' S5 E
; X9 v/ L! `; v9 G1 ?0 x% a' v3 }
! c% ^ j8 e9 Z! n, B$ yCurrently available feasibility data for possible combination strategies.
6 i: {" x1 U# P/ q- p————————————————————————————————
0 o8 M; B" M( ?% |Combination Feasibility according to preliminary data
/ m O6 A2 b! i; k- `% W——————————————————————————————————
2 B. ~& U' Z+ B2 C: R' NBevacizumab + sorafenib Yes, reduced dose & u- D3 O9 s9 E" B
Bevacizumab + sunitinib† No 7 G$ V+ Y, A: o2 d" W n& P" \
Bevacizumab + temsirolimus Yes & J& q+ U* L5 J
Bevacizumab + everolimus Yes
- x: E0 x( A" F) u2 O3 zSorafenib + sunitinib ? " @# |) R; R f
Sorafenib + temsirolimus Yes, reduced dose
9 g+ v6 D+ v1 i% hSorafenib + everolimus Yes, reduced dose & I) h- r2 t: g, b0 }- f
Sunitinib + temsirolimus† No ; i- c$ N7 T* a7 H( f8 D9 e' h% Y
Sunitinib + everolimus ?
, g6 s" Y) c p+ N7 jTemsirolimus + everolimus ?
2 M# F$ ?% f8 a5 L/ f" n————————————————————. |. U/ T9 E q" A# v# o
†Led to US FDA warning.- ?. P0 Y$ f* ? W/ e# @: \- `/ }
?: As yet unattempted combination.
% u& x8 l C( M3 [, m/ q |
显身卡
3 {8 d6 U+ y8 i/ o
